Affimed N.V. (AFMD) Stock Analysis

Affimed N.V. (AFMD) Healthcare & Pipeline Overview

Affimed N.V. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, particularly through its proprietary Redirected Optimized Cell Killing (ROCK) platform. The company's lead candidate, AFM13, targets CD30-positive lymphomas, positioning Affimed within the competitive landscape of oncology-focused biotechnology firms.

What Is the Investment Thesis for AFMD?

Affimed N.V. presents a notable research candidate within the biotechnology sector, driven by its innovative ROCK platform and promising clinical pipeline. The company's lead candidate, AFM13, has shown encouraging results in clinical trials for CD30-positive lymphomas, addressing a significant unmet medical need. Key value drivers include the successful advancement of AFM13 through regulatory milestones and potential commercialization. The ongoing Phase IIa trial for AFM24 in advanced cancers represents another catalyst. However, the company's negative profit margin of -1280.2% and reliance on clinical trial outcomes pose risks. Successful execution of clinical trials and strategic partnerships are crucial for realizing the company's potential.

Based on FMP financials and quantitative analysis

AFMD Key Highlights

Affimed N.V. is a clinical-stage biopharmaceutical company focused on cancer immunotherapies.

• Lead product candidate AFM13 has completed Phase II clinical study for peripheral T-cell lymphoma.
• AFM24, a tetravalent, bispecific epidermal growth factor receptor, is in Phase IIa clinical trial for advanced cancers.
• Affimed's ROCK platform enables the development of bispecific antibodies that redirect and activate natural killer (NK) cells.
• The company has collaboration agreements with The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd.

Who Are AFMD's Competitors?

AFMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AFMD's Key Strengths?

Proprietary ROCK platform for generating bispecific antibodies.

• Clinical pipeline of ICE molecules targeting various cancers.
• Strategic collaborations with leading institutions and pharmaceutical companies.
• Expertise in innate immunity and cancer immunotherapy.

What Are AFMD's Weaknesses?

Clinical-stage company with no currently marketed products.

• High research and development expenses.
• Dependence on successful clinical trial outcomes.
• Negative profit margin.

What Could Drive AFMD Stock Higher?

Data readout from the Phase IIa clinical trial of AFM24 in advanced cancers.

• Initiation of new clinical trials for AFM13 in additional indications.
• Advancement of AFM28 and AFM32 through preclinical development.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for AFMD?

Financial-distress signal — its Altman Z-Score of -25.63 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for AFM13, AFM24, or other pipeline candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other biotechnology and pharmaceutical companies.
• High research and development expenses.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for AFMD?

• Growth opportunity 1: Expansion of AFM13 into new indications represents a significant growth opportunity. While currently focused on CD30-positive lymphomas, AFM13's mechanism of action could potentially be applied to other hematological malignancies or even solid tumors expressing CD30. This expansion would require further clinical trials and regulatory approvals, but could significantly broaden the market opportunity for AFM13. The timeline for this expansion would depend on the success of ongoing and future clinical trials, with potential for new indications emerging within the next 3-5 years. The market size for additional CD30-expressing cancers could add significantly to the potential revenue stream.
• Growth opportunity 2: Advancing AFM24 through clinical development for advanced cancers is a key growth driver. AFM24, targeting EGFR and CD16A, has the potential to address a wide range of solid tumors. Successful completion of the Phase IIa clinical trial and subsequent progression through later-stage trials could lead to regulatory approval and commercialization. The market for EGFR-targeted therapies is substantial, with numerous approved drugs already available. AFM24's unique mechanism of action, engaging the innate immune system, could provide a competitive advantage. The timeline for potential commercialization is estimated at 3-5 years, contingent on clinical trial outcomes.
• Growth opportunity 3: Strategic partnerships and collaborations can accelerate Affimed's growth. The company already has collaborations with major players like Genentech and Roivant Sciences. Expanding these partnerships or forming new alliances with other pharmaceutical companies or research institutions could provide access to additional funding, expertise, and resources. These collaborations could also facilitate the development and commercialization of Affimed's pipeline candidates. The timeline for new partnerships is uncertain, but ongoing discussions and networking efforts could lead to new agreements within the next 1-2 years. The financial impact of these partnerships could be significant, providing non-dilutive funding and potential revenue streams.
• Growth opportunity 4: Development of novel ICE (Innate Cell Engager) molecules beyond AFM13 and AFM24 represents a long-term growth opportunity. Affimed's ROCK platform allows for the generation of ICE molecules targeting a wide range of tumor-associated antigens. Expanding the pipeline with new ICE candidates could address unmet medical needs in various cancer types. The preclinical development of AFM28 and AFM32 demonstrates Affimed's commitment to innovation. The timeline for these new ICE candidates to reach clinical development is estimated at 2-4 years, with potential commercialization several years later. The market potential for these new ICE molecules would depend on the specific targets and indications.
• Growth opportunity 5: Geographic expansion into new markets, particularly Asia, represents a significant growth opportunity. While Affimed currently focuses on the United States, Germany, and the rest of Europe, expanding into Asia, with its large and growing population, could significantly increase the company's potential market reach. This expansion would require establishing a presence in these markets, conducting clinical trials in local populations, and obtaining regulatory approvals. The timeline for geographic expansion is estimated at 3-5 years, with initial efforts focused on establishing partnerships and conducting market research. The potential revenue from Asian markets could be substantial, given the high prevalence of cancer in these regions.

What Are AFMD's Competitive Advantages?

• Proprietary ROCK platform for generating bispecific antibodies.
• Clinical pipeline of ICE molecules targeting various cancers.
• Strategic collaborations with leading institutions and pharmaceutical companies.
• Expertise in innate immunity and cancer immunotherapy.

What Does AFMD Do?

Affimed N.V., founded in 2000 and headquartered in Heidelberg, Germany, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer immunotherapies. The company's primary focus is on harnessing the power of the innate immune system to fight cancer. Affimed's proprietary Redirected Optimized Cell Killing (ROCK) platform allows for the generation of bispecific antibodies that redirect and activate natural killer (NK) cells to selectively kill tumor cells. Their lead product candidate, AFM13, is a tetravalent bispecific antibody targeting CD30, a protein expressed on certain lymphoma cells, and CD16A on NK cells. AFM13 has completed Phase II clinical study for peripheral T-cell lymphoma and is in Phase IIa clinical trial for CD30-positive lymphoma, as well as Phase I clinical trial for Hodgkin lymphoma. In addition to AFM13, Affimed is developing a pipeline of other ICE (Innate Cell Engager) molecules, including AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR), and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an ICE, which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed has established collaborations with leading institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd., as well as a research funding agreement with The Leukemia & Lymphoma Society, to advance its research and development efforts. Affimed N.V. was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.

What Products and Services Does AFMD Offer?

• Affimed discovers and develops cancer immunotherapies.
• They utilize the Redirected Optimized Cell Killing (ROCK) platform.
• Their lead product candidate is AFM13, targeting CD30-positive lymphomas.
• They are developing AFM24 for the treatment of advanced cancers.
• They are developing AFM28 for the treatment of acute myeloid leukemia.
• They are developing AFM32 for the treatment of solid tumors.
• Affimed collaborates with leading institutions and pharmaceutical companies to advance their research.

How Does AFMD Make Money?

• Affimed focuses on research and development of cancer immunotherapies.
• They generate revenue through collaboration agreements and partnerships.
• They seek to monetize their drug candidates through licensing or commercialization after successful clinical trials.

What Industry Does AFMD Operate In?

Affimed N.V. operates within the rapidly evolving biotechnology industry, specifically focusing on cancer immunotherapy. The market for cancer immunotherapies is experiencing substantial growth, driven by advancements in understanding the role of the immune system in fighting cancer. Competitive landscape includes major pharmaceutical companies and specialized biotech firms developing novel immunotherapies, such as bispecific antibodies and cell therapies. Affimed's ROCK platform and focus on innate immunity offer a differentiated approach within this competitive environment.

Who Are AFMD's Key Customers?

• Patients with cancer, particularly lymphomas and solid tumors.
• Pharmaceutical companies through collaboration and licensing agreements.
• Healthcare providers who will prescribe and administer Affimed's therapies.

Wall Street analysts project Affimed N.V. revenue of about $2.2M for fiscal 2026, with EPS near $-1.38.

Affimed N.V. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.1% above estimates on average.

Affimed N.V.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.63 places it in the distress zone, a signal of elevated financial risk.

AFMD Revenue & Earnings Trend

In Q3 FY2024, AFMD generated $180K in top-line revenue, marking a sequential increase of 0.6%. The company recorded a net loss of $17.6M, with diluted EPS of $-1.09. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare.

Company Profile

Affimed N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mannheim, DE. The company is led by CEO Shawn Leland. AFMD has traded publicly since 2014.

AFMD Financials

AFMD Latest News

Common Questions About AFMD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources